Menu
Back to Journals » Neuropsychiatric Disease and Treatment » Volume 6 » Issue 1
The role of glatiramer acetate in the early treatment of multiple sclerosis
Authors Brandes D
Published 9 June 2010 Volume 2010:6(1) Pages 329—336
DOI https://doi.org/10.2147/NDT.S5898
Review by Single anonymous peer review
Peer reviewer comments 3
David W Brandes
Hope MS Center, Knoxville, TN, USA; ULCA, Los Angeles, CA, USA
Abstract: The treatment of the underlying disease process causing multiple sclerosis has continued to evolve since the initial approval of interferon-beta-1b in 1993. Current emphasis is on early treatment, including treatment after a single clinical attack (clinically isolated syndrome). The assessment of which disease modifying medication to use as initial therapy has continued to remain a combination of science and the art of medicine. Equally important are the assessment of treatment failure and the subsequent choice of medication change. This article will present scientific information, as well as information about clinical decision making, about these choices, with emphasis on the changing role of glatiramer acetate in this process.
Keywords: glatiramer acetate, early treatment, multiple sclerosis
© 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.